Catalent Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 03:00PM GMT
Juan Esteban Avendano - BofA Merrill Lynch, Research Division - Associate

(technical difficulty)

Bank of America Healthcare Conference. I'm Juan Avendano, I'm one of analysts in the life sciences tools team run by Derik De Bruin. I focus on CROs and CDMOs. And here to kick it off, we have Catalent; their CFO, Wett Joseph; and Tom Castellano from IR. With that said, welcome, gentlemen. Pleasure to have you here once again. Wetteny, if you could please start up by just giving us some general comments on Catalent, the evolution of the company and where you see it now.

Wetteny N. Joseph - Catalent, Inc. - Senior VP & CFO

Sure. Thank you, Juan. And thanks for having us. Catalent is the world leader in advanced delivery dosage technologies and development solutions. We serve approximately 1,000 customers, supplying product into over 80 countries and really supply more than 70 billion doses a year. This is approximately 1 in every 20 doses taken across prescription and consumer. We're organized around 4 business segments. We have a Softgel business that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot